Studied at the Karolinska Institutet and received his doctorate in molecular pharmacology in 1985, with over 28 years of experience in pharmaceutical research and development. Member of Swedish physiology and Swedish pharmaceutical society, vice President of Western Returned Scholars Association of guizhou, member of tumor immunology and biotherapy professional committee of Chinese anti-cancer association, vice President of China Clinical Translational Medicine Industry Society, of Health Industry and Enterprise Management, leader of biotherapy group, director of clinical medical research center of affiliated hospital of Guizhou Medical University. From 1991 to 2009, he was successively employed in astrazeneca, famasia (later Pfizer), Biovitrum and other international pharmaceutical companies, engaged in new drug development, and served as senior researcher, project leader and manager of new drug r&d department. After returning to China in 2010, he founded jiangsu telui shengnuo bio-pharmaceutical technology co., LTD., guizhou shengnuo bio-technology co., LTD., hangzhou nuoda pharmaceutical co., LTD., and acquired Sweden's SentoClone International AB.

Studied at the Karolinska Institutet and received her doctorate in pharmacology in 2002. In 2004, he founded the TONGDA technology consulting company in Sweden. In 2006, she joined Unilever R&D, responsible for coordinating the development of international projects in China, Europe, India and other regions, and was rated as Unilever's high-potential talent. In 2011, she established the Guizhou terui shengnuo bio-pharmaceutical co., LTD. And from 2014 till now, she was severed as chief physician of tumor biotherapy center of affiliated hospital of guizhou medical university and medical practitioner of karolinska university hospital of Sweden.

Graduated from college of chemical engineering, Inner Mongolia University of Technology in 2003. From 2004 to 2010, he was successively employed by Beijing tingle laikei medical appliances, blue cross bio-medical (Beijing), Shenzhen hiprec pharmaceutical, Shenzhen Scienceway bio-technologies and other pharmaceutical companies, engaged in product research, development and registration, production and project management (preclinical and Clinical trials). From 2010 to now, he has been the project director of Jiangsu Sinorda biomedical technology and Hangzhou Sinorda pharmaceutical, responsible for project management and business development of China-Sweden innovative medicine.

He received his PhD from Beijing Normal University and is a visiting scholar at the cancer research center of Karolinska institute, Sweden. As the chief project officer of Guizhou Sinorda pharmaceutical, he has many years of experience in tumor immunology and molecular biology research, and has participated in several National Natural Science Funds and “12th Five Year Plan” National Science and Technology Major Projects for “Major New Drugs Innovation and Development” (The Ⅰ - Ⅲ period clinical research and development of anti-tumor T cell vaccine 2013 zx09101015).